Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 161Nivolumab 133Ipilimumab 78Cyclophosphamide 47Specimen Handling 43Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 29trametinib 24relatlimab 24binimetinib 23Interleukin-2 22fludarabine phosphate 21dabrafenib 20atezolizumab 19Radiotherapy 19Opdualag 19aldesleukin 18Radiosurgery 18CTLA-4 Antigen 18encorafenib 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lifileucel 11lenvatinib 11Bevacizumab 11Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rosiglitazone × Dermatologic × 1 year × Clear all
NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

University of Pittsburgh

Phase 2 Recruiting
72 enrolled
DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡